Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV
Journal of Neurochemistry (2006)
Russian sleep researchers Kovalzon and Strekalova argue that after three decades of work, the 'DSIP is a sleep factor' hypothesis remains weakly documented — no receptor identified, no gene confirmed, no consistent acute sleep-induction effect in standardised paradigms. The most rigorous published skepticism toward the foundational DSIP claim.
This 2006 Journal of Neurochemistry review by Vladimir Kovalzon and Tatyana Strekalova — Russian sleep researchers who worked extensively on DSIP behavioural pharmacology in the 1990s — is the most rigorous published statement of skepticism toward the foundational DSIP-as-sleep-factor hypothesis. The authors review the literature from Schoenenberger's 1977 dialysate isolation and 1978 nonapeptide synthesis (Schoenenberger 1978) through the European clinical-trial era (Schneider-Helmert 1986, 1987) and the Russian behavioural-pharmacology programme of the 1990s, and conclude that the "DSIP is a sleep factor" claim is still extremely poorly documented. Key gaps they identify: the gene encoding a precursor protein for DSIP has not been found; no specific DSIP receptor has been identified; the acute sleep-induction effect of synthetic DSIP in standardised animal paradigms is inconsistent across laboratories; and the clinical-trial findings, while suggestive, rest on small sample sizes from a small number of investigators. The authors do summarise the molecule's documented effects (stress-response modulation, neuroprotection in oxidative-stress models, antioxidant activity, behavioural anxiolytic-like effects in rodents) and argue that DSIP may turn out to have a real biological role distinct from sleep induction — but that the original framing as an endogenous sleep factor has not been substantiated.
This is a narrative review, not new primary data. The Russian sleep-research community has had a distinct relationship with the DSIP literature — both as a source of primary behavioural-pharmacology data and as a critical readership of the Swiss / European clinical work — and the review's framing reflects that internal-community perspective rather than a fully external assessment. The "no receptor identified" claim was accurate in 2006 and remains essentially accurate twenty years later; the few candidate-receptor reports that have emerged have not been independently replicated. Readers should read the paper in tandem with Schoenenberger 1978 (the foundational discovery) and Schneider-Helmert 1986/1987 (the strongest clinical evidence) rather than as a standalone account — the Kovalzon view is the field's strongest skeptical voice but not its consensus position. The neuroprotective and antioxidant effects the review summarises are real and remain a plausible alternative biological niche for DSIP, but they are not the basis on which the molecule is marketed in modern consumer-peptide channels.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.